BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: Since the combination of a TKI and ABT-737 overcame resistance in BIM deletion polymorphism-containing K562 clones, feasibility of this combination in imatinib-resistant primary CML cells, with or without the BIM deletion polymorphism, was assessed.